LocoMMotion: A study of real-life current standards of care in triple-class exposed patients with relapsed/refractory multiple myeloma – 2-year follow-up (final analysis)

The treatment of relapsed/refractory multiple myeloma (RRMM) is particularly difficult as patients become resistant to available drug classes. The LocoMMotion study, with 248 participants and a median follow-up of 26.4 months, revealed that real-world clinical practice (RWCP) regimens in triple-class exposed (TCE) RRMM patients had limited success, with an overall response rate of 31.9%, median progression-free survival (PFS) of 4.6 months, and overall survival of 13.8 months. The study highlights the lack of standardized treatments and the urgent need for therapies with novel mechanisms to improve outcomes in TCE patients.